Leptin and insulin homeostasis in epilepsy: Relation to weight adverse conditions

Epilepsy Research

Volumn 75, Issue 1, 2007, Pages 1-9

  Hamed, Sherifa A ^a  

^a ASSIUT UNIVERSITY   (Egypt)

Author keywords

Antiepileptic drugs; Epilepsy; Insulin; Leptin; Valproate; Weight gain

Indexed keywords

4 AMINOBUTYRIC ACID; ADIPONECTIN; ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; FATTY ACID; FELBAMATE; GABAPENTIN; GHRELIN; GLUCOSE; INSULIN; LAMOTRIGINE; LEPTIN; OXCARBAZEPINE; PHENYTOIN; PREGABALIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ADIPOCYTE; ANTICONVULSANT THERAPY; APPETITE; ATHEROSCLEROSIS; BODY WEIGHT; CALORIC INTAKE; CENTRAL NERVOUS SYSTEM; DRUG EFFECT; DRUG SUBSTITUTION; EPILEPSY; FATTY LIVER; FEEDING BEHAVIOR; HOMEOSTASIS; HORMONAL REGULATION; HORMONE ACTION; HORMONE BLOOD LEVEL; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; HYPERLEPTINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LOW DRUG DOSE; MENTAL DISEASE; NEUROLOGIC DISEASE; NEUROTRANSMISSION; NONHUMAN; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; REVIEW; RISK; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALS; ANTICONVULSANTS; BODY WEIGHT; EPILEPSY; HOMEOSTASIS; HUMANS; INSULIN; LEPTIN; VALPROIC ACID;

EID: 34249780805     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2007.04.001     Document Type: Review

References (115)

1. Aiston S., and Agius L. Leptin enhances glycogen storage in hepatocytes by inhibition of phosphorylase and exerts an additive effect with insulin. Diabetes 48 (1999) 15-20
2. Argente J., Barrios V., Chowen A.J., Sinha M.K., and Considine R.V. Leptin plasma levels in healthy Spanish children and adolescents, children with obesity, and adolescents with anorexia nervosa and bulimia nervosa. J. Pediatr. 131 (1997) 833-838
3. Arroy S., et al. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose response study in adults with partial seizures. Epilepsia 45 (2004) 20-27
4. Aydin K., Serdaroglu A., Okuyaz C., Bidect S., and Gucuyener K. Serum insulin, leptin, and neuropeptide Y levels in epileptic children treated with valproate. J. Child Neurol. 20 (2005) 848-851
5. Banks W.A., Niehoff M.L., Martin D., and Farrell C.L. Leptin transport across the blood-brain barrier of the Koletsky rat is not mediated by a product of the leptin receptor gene. Brain Res. 950 (2002) 130-136
6. Ben-Menachem E., Axelsen M., Johanson E.H., Stagge A., and Smith U. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes. Res. 11 (2003) 556-562
7. Bhatt R., Bhatt S., Rameshwar P., and Siegel A. Amygdaloid kindled seizures induce weight gain that reflects left hemisphere dominance in rats. Physiol. Behav. 82 (2004) 581-587
8. Biton V. Effect of antiepileptic drugs on bodyweight: overview and clinical implications for the treatment of epilepsy. CNS Drugs 17 11 (2003) 781-791
9. Biton V., Levisohn P., Hoyler S., Vuong A., and Hammer A.E. Lamotrigine versus valproate monotherapy-associated weight change in adolescents with epilepsy: results from a post hoc analysis of a randomized, double-blind clinical trial. J. Child Neurol. 18 (2003) 133-139
10. Biton V., Mirza W., Montouris G., Vuong A., Hammer A.E., and Barrett P.S. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 56 (2001) 172-177
11. Bowden C.L., Calabrese J.R., Ketter T.A., Sachs G.S., White R.L., and Thompson T.R. Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar 1 disorder. Am. J. Psychiatry 163 7 (2006) 1199-1201
12. Breum L., Astrup A., Gram L., Andersen T., Stokholm K.H., Christensen N.J., Werdelin L., and Madsen J. Metabolic changes during treatment with valproate in humans: implication for untoward weight gain. Metabolism 41 (1992) 666-670
13. Brodersen R., Jorgensen N., Vorum H., and Krukow N. Valproate and palmitate binding to human serum albumin: an hypothesis on obesity. Mol. Pharmacol. 37 (1990) 706-709
14. Cases J.A., Gabriely I., Ma X.H., Yang X.M., Michaeli T., Fleischer N., Rossetti L., and Barzilai N. Physiological increase in plasma leptin inhibits insulin secretion in vivo. Diabetes 50 (2001) 348-357
15. Ciccone M., Vettor R., Pannacciulli N., Minenna A., Bellacicco M., Rizzon P., Giorgino R., and De Pergola G. Plasma leptin is independently associated with the intima-media thickness of the common carotid artery. Int. J. Obes. Relat. Metab. Disord. 25 6 (2001) 805-810
16. Cohen B., Novick D., and Rubinstein M. Modulation of insulin activities by leptin. Science 274 (1996) 1185-1188
17. Considine R.V. Human leptin: an adipocyte hormone with weight-regulatory and endocrine functions. Semin. Vasc. Med. 5 1 (2005) 15-24
18. Corman C.L., Leung N.M., and Guberman A.H. Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. Can. J. Neurol. Sci. 24 (1997) 240-244
19. Covanis A., Gupta A.K., and Jeavons P.M. Sodium valproate: monotherapy and polytherapy. Epilepsia 23 (1982) 693-720
20. Cowley M.A., Smart J.L., Rubenstein M., Cerdan M.C., Diano S., Horvath T.L., Cone R.D., and Low M.J. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature 411 (2001) 480-484
21. Degawai-Yamauchi M., Moss K.A., Bovenkerk J.E., Shankar S.S., Morrison C.L., Lelliott C.J., Vidal-Puig A., Jones R., and Considine R.V. Regulation of adiponectin expression in human adipocyte; effects of adipocity, glycocorticoids, and tumor necrosis factor alpha. Obes. Res. 13 (2005) 662-669
22. Demir E., and Aysun S. Weight gain associated with valproate in childhood. Pediatr. Neurol. 22 (2000) 361-364
23. DeToledo J.C., Toledo C., DeCerce J., and Ramsay R.E. Changes in body weight with chronic, high-dose gabapentin therapy. Ther. Drug Monit. 19 (1997) 394-396
24. Diez J.J., and Igleasis P. The role of novel adipocyte-derived hormone adiponectin in human disease. Eur. J. Endocrinol. 148 (2003) 293-300
25. Dinesen H., Gram L., Andersen T., and Dam M. Weight gain during treatment with valproate. Acta Neurol. Scand. 69 (1984) 65-69
26. Drieling, T, Biedermann, N.C., Scharer, L.O., Strobi, N., Langosch, J.M., 2006. Psychotropic drug-induced changes of weight: a review. Fortschr Neurol. Psychiatry (Epub a head in print) (abstract).
27. Easter D., O'Brvan-Tear C.G., and Verity C. Weight gin with valproate or carbamazepine-a reappraisal. Seizure 6 2 (1997) 121-125
28. Egger J., and Brett E.M. Effects of sodium valproate in 100 children with special reference to weight. BMJ 283 (1981) 577-580
29. Egido E.M., Rodriguez-Gallardo J., Silvestre R.A., and Marco J. Inhibitory effect of ghrelin on insulin and pancreatic somatostatin secretion. Eur. J. Endocrinol. 146 (2002) 241-244
30. Elmquist J.K., Elias C.F., and Saper C.B. From lesions to leptin: hypothalamic control of food intake and body weight. Neuron 22 (1999) 221-232
31. Fruebis J., Tsao T.S., Javorschi S., Ebbets-Reed D., Erickson M.R., Yen F.T., Bihain B.E., and Lodish H.F. Proteolytic cleavage product of 30-kDa adipocte complement-related protein increases fatty acid oxidation in muscle causes weight loss in mice. PNAS 98 (2001) 2005-2010
32. Gidal B.E., Sheth R.D., Magnus L., and Herbeuval A.F. Levetiracetam does not alter body weight: analysis of randomized, controlled clinical trials. Epilepsy Res. 56 (2003) 121-126
33. Gil-Campos M., Canete R., and Gil A. Adiponectin, the missing link in insulin resistance and obesity. Clin. Nutr. 23 (2004) 963-974
34. Glauser T.A. Oxcarbazepine in the treatment of epilepsy. Pharmacotherapy 21 (2001) 904-919
35. Greco R., Latini G., Chiarelli F., Iannetti P., and Verrotti A. Leptin, ghrelin and adiponectin in epileptic patients treated with valproic acid. Neurology 65 (2005) 1808-1809
36. Grill V., and Ovigstad E. Fatty acids and insulin secretion. Br. J. Nutr. S1 (2000) S79-S84
37. Hamed S.A., and Abdellah M.M. Trace elements and electrolytes homeostasis and their relation to antioxidant enzyme activity in brain hyperexcitability of epileptic patients. Jpn. J. Pharmacol. Sci. 96 (2004) 349-359
38. Hamed S.A., Hamed E.A., Kandil M.R., El-Shereef H.K., Abdellah M.M., and Omar H. Serum thyroid hormone balance and lipid profile in patients with epilepsy. Epilepsy Res. 66 (2005) 173-183
39. Hamed S.A., Mohamed K.A., EL-taher A.M., Hamed E.A., and Omar H. The sexual and reproductive health in men with generalized epilepsy: a multidisciplinary evaluation. Int. J. Impotence Res. 18 (2006) 287-292
40. Hamed S.A., and Nabeshima T. The high atherosclerotic risk among epileptics: the atheroprotective role of multivitamins. Jpn. J. Pharmacol. Sci. 98 4 (2005) 340-353
41. Harrold J.A. Hypothalamic control of energy balance. Curr. Drug Targets 5 3 (2004) 207-219
42. Harvey J., and Ashford M.L. Leptin in the CNS: much more than a satiety signal. Neuropharmacology 44 7 (2003) 845-854
43. Havel P.J. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr. Opin. Lipidol. 13 1 (2002) 51-59
44. Haynes W.G., Morgan D.A., Walsh S.A., Mark A.L., and SIvitz W.I. Receptor-mediated regional sympathetic nerve activation by leptin. J. Clin. Invest. 100 (1997) 270-278
45. Hauser W.A. Incidence and prevalence. In: Engel J., and Pedley T.A. (Eds). Epilepsy: A Comprehensive Textbook (1997), Lippincott-Raven, Philadelphia 47-57
46. Hogan R.E., Bertrand M.E., and Deaton R.L. Total percentage body weight changes during add-on therapy with tiagabine, carbamazepine and phenytoin. Epilepsy Res. 41 10 (2000) 23-28
47. Horvath T.L., Diano S., Sotonyi P., Heiman M., and Tschop M. Mini-review: gherlin and the regulation of energy balance-a hypothalamic perspective. Endocrinology 142 (2001) 4163-4169
48. Hotta K., Funahashi T., Arita Y., Takahashi M., Matsuda M., Okamoto Y., Iwahashi H., Kuriyama H., Ouchi N., Maeda K., Nishida M., Kihara S., Sakai N., Nakajima T., Hasegawa K., Maroguchi M., Ohmoto Y., Nakamura Y., Yamashita S., Hanafusa T., and Matsuzawa Y. Plasma concentrations of a novel adipose-specific protein, adiponectin, in type 2 diabetes patients. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 1595-1599
49. Isojarvi J.I., Laatikainen T.J., Pakarinen A.J., Juntunen K.T., and Myllyla V.V. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N. Engl. J. Med. 329 (1993) 1383-1388
50. Isojarvi J.I., Rattya J., Myllyla V.V., Knip M., Koivunen R., Pakarinen A.J., Tekay A., and Tapanainen J.S. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann. Neurol. 43 (1998) 446-451
51. Isojarvi J.I., Tauboll E., Tapanainen J.S., Pakarinen A.J., Laatikainen T.J., Knip M., and Myllyla V.V. On the association between valproate and polycystic ovary syndrome: a response and an alternative view. Epilepsia 42 (2001) 305-310
52. Jallon P., and Picard F. Bodyweight gain and anticonvulsants: a comparative review. Drug Saf 24 13 (2001) 969-978
53. Joffe H., Hall J.E., Cohen L.S., Taylor A.E., and Baldessarini R.J. A putative relationship between valproic acid and polycystic ovarian syndrome: implications for treatment of women with seizure and bipolar disorders. Harv. Rev. Psychiatry 11 (2003) 99-108
54. Johannessen C.U. Mechanism of action of Valproate: a commentary. Neurochem. Int. 37 92-93 (2000) 103-110
55. Kanai F., Ito K., Todaka M., Hayashi H., Kamohara S., Ishii K., Okada T., Hazeki O., Ui M., and Ebina Y. Insulin-stimulated GLUT4 translocation is relevant to the phosphorylation of IRS-1 and the activity of PI2-kinase. Biochem. Biophys. Res. Commun. 195 (1993) 762-768
56. Kawachi I. Physical and psychological consequences of weight gain. J. Clin. Psychiatry 60 (1999) 5-9
57. Ketter T.A., Post R.M., and Theodore W.H. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 53 5 Suppl. 2 (1999) S53-S67
58. Kim M.S., Pak Y.K., Jang P.G., Namkoong C., Choi Y.S., Won J.C., Kim K.S., Kim S.W., Kim H.S., Park J.Y., Kim Y.B., and Lee K.U. Role of hypothalamic Foxo1 in the regulation of food intake and energy homeostasis. Nat. Neurosci. 9 7 (2006) 901-906
59. Korbonits M., Goldstone A.P., GUeorguiev M., and Grossman A.B. Ghrelin-a hormone with multiple functions. Front Neuronendocrinol. 24 (2004) 27-68
60. Lagace D.C., Mcleod R.S., and Nachtigal M.W. Valproic acid inhibits leptin secretion and reduces leptin messenger ribonucleic acid levels in adipocytes. Endocrinology 145 12 (2004) 5493-5503
61. Loiseau P. Review of controlled trials of Gabitril (tiagabine): a clinician's viewpoint. Epilepsia 40 S9 (1999) S14-S19
62. Luef G., Abraham I., Hoppichler F., Trinka E., Unterberger I., Bauer G., and Lechleitner M. Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy. Metabolism 51 10 (2002) 1274-1278
63. Luef G.J., Lechleitner M., Bauer G., Trinka E., and Hengster P. Valproic acid modulates islet cell insulin secretion: a possible mechanism of weight gain in epilepsy patients. Epilepsy Res. 55 (2003) 53-58
64. Luef G.J., Waldmann M., Sturm W., Naser A., Trinka E., Unterberger I., Bauer G., and Lechleitner M. Valproate therapy and nonalcoholic fatty liver disease. Ann. Neurol. 55 (2004) 729-732
65. MacGarry J.D. Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 51 (2002) 7-18
66. Maggioni F., Ruffatti S., Dainese F., Mainardi F., and Zanchin G. Weight variations in the prophylactic therapy of primary headaches: 6-month follow-up. J. Headache Pain 6 4 (2005) 322-324
67. McIntyre R.S., Mancini D.A., McCann S., Srinivasan J., and Kennedy S.H. Valproate, bipolar disorder and polycystic ovarian syndrome. Bipolar Disord. 5 (2003) 28-35
68. McElroy S.L., Suppes T., Keck P.E., et al. Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol. Psychiatry 47 (2000) 1025-1033
69. McTigue K., Larson J.C., Valoski A., Burke G., Kotchen J., Lewis C.E., Stefanick M.L., Van Horn L., and Kuller L. Mortality and cardiac and vascular outcomes in extremely obese women. JAMA 296 1 (2006) 79-86
70. Meeker R.B., and Myers R.D. GABA and glutamate: possible metabolic intermediaries involved in the hypothalamic regulation of food intake. Brain Res. Bull. 5 (1980) 253-259
71. Muoio D.M., Dohm G.L., Tapscott E.B., and Coleman R.A. Leptin opposes insulin's effects on fatty acid partitioning in muscles isolated from obese ob/ob mice. Am. J. Physiol. 276 (1999) E913-E921
72. Nelson-DeGrave V.L., Wickenheisser J.K., Cockrell J.E., Wood J.R., Legro R.S., Strauss III J.F., and McAllister J.M. Valproate potentiates androgen biosynthesis in human ovarian theca cells. Endocrinology 145 (2004) 799-808
73. Ness-Abramof R., and Apovian C.M. Drug-induced weight gain. Drugs Today (Barc) 41 8 (2005) 547-555
74. Nisoli E., Carruba M.O., Tonello C., Macor C., Federspil G., and Vettor R. Induction of fatty acid translocase/CD36, peroxisome proliferator-activated receptor-gamma2, leptin, uncoupling proteins 2 and 3, and tumor necrosis factor-alpha gene expression in human subcutaneous fat by lipid infusion. Diabetes 49 (2000) 319-324
75. Niswender K.D., Morrison C.D., Clegg D.J., Olson R., Baskin D.G., Myers Jr. M.G., Seeley R.J., and Schwartz M.W. Insulin activation of phosphatidylinositol 3-kinase in the hypothalamic arcuate nucleus: a key mediator of insulin-induced anorexia. Diabetes 52 (2003) 227-231
76. Novak G.P., Maytal J., Alshansky A., Eviatar L., Sy-Kho R., and Siddique Q. Risk of excessive weight gain in epileptic children treated with valproate. J. Child Neurol. 14 (1999) 490-495
77. Parhami F., Tintut Y., Ballard A., Fogelman A.M., and Demer L.L. Leptin enhances the calcification of vascular cells: artery wall as a target of leptin. Circ. Res. 88 9 (2001) 954-960
78. Pasquali R., and Casimirri F. The impact on hyperandrogenism and polycystic ovary syndrome in premenopausal women. Clin. Endocrinol. 39 (1993) 1-16
79. Peiris A.N., Mueller R.A., Sruve M.F., Smith G.A., and Kissebah A.H. Relationship of androgenic activity to splanchnic insulin metabolism and peripheral glucose utilization in premenopausal women. J. Clin. Endocrinol. Metab. 164 (1987) 162-169
80. Pelleymounter M.A., Cullen M.J., Baker M.B., Hecht R., Winters D., Boone T., and Collins F. Effects of obese gene product on body weight regulation in ob/ob mice. Science 269 (1995) 540-543
81. Ponchaut S., and Veitch K. Valproate and mitochondria. Biochem. Pharmacol. 46 (1993) 199-204
82. Pylvanen V., Knip M., Pakarinen A., Kotila M., Turkka J., and Isojarvi J.I. Serum insulin and leptin levels in valproate-associated obesity. Epilepsia 43 (2002) 514-517
83. Pylvanen V., Pakarinen A., Knip M., and Isojarvi J. Characterization of insulin secretion in valproate-treated patients with epilepsy. Epilepsia 47 90 (2006) 1460-1464
84. Raeven G.M. Role of insulin resistance in human disease. Diabetes 37 (1988) 1595-1604
85. Rattya Y.A., Vainionpaa L., Knip M., Lanning P., and Isojarvi J.I. The effects of valproate, carbamazepine and oxcarbamazepine on growth and sexual maturation in girls with epilepsy. Pediatrics 103 (1999) 588-593
86. Reiterer E.E., Sudi K.M., Mayer A., Limbert-Zinterl S., Stalzer-Brunner C., Fuger G., and Borkenstein M.H. Changes in leptin and insulin composition in obese children during a weight reduction program. J. Pediatr. Endocrinol. Metab. 12 (1999) 853-862
87. Richard D., and Baraboi D. Circuitries involved in the control of energy homeostasis and the hypothalamic-pituitary-adrenal axis activity. Treat Endocrinol. 3 5 (2004) 269-277
88. Richard D., Ferland J., Lanlonde J., Samson P., and Deshales Y. Influence of topiramate in the regulation of energy balance. Nutrition 16 10 (2000) 961-966
89. Richens A., Davidson D.L., Cartlidge N.E., Easter D.J., and Adult EPITEG Collaborative Group. A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy. J. Neurol. Neurosurg. Psychiatry 57 (1994) 765-771
90. Roden M., Krssak M., Stingl H., Gruber S., Hofer A., Furnsinn C., Moser E., and Waldhausl W. Rapid impairment of skeletal muscle glucose transport/physphorylation by free fatty acids in humans. Diabetes 48 (1999) 358-364
91. Rollins B.L., and King B.M. Amygdala-lesion obesity: what is the role of the various amygdaloid nuclei?. Am. J. Physiol. Regul. Integr. Comp. Physiol. 279 (2000) R1348-R1356
92. Russell C.D., Petersen R.N., Rao S.P., Ricci M.R., Prasad A., Zhang Y., Brolin R.E., and Fried S.K. Leptin expression in adipose tissue from obese humans: depot-specific regulation by insulin and dexamethasone. Am. J. Physiol. 275 3 Pt 1 (1998) E507-E515
93. Sahu A. A hypothalamic role in energy balance with special emphasis on leptin. Minireview. Endocrinology 145 6 (2004) 2613-2620
94. Segal K.R., Landt M., and Klein S. Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. Diabetes 45 (1996) 988-991
95. Shanley L.J., O'Malley D., Irving A.J., Ashford M.L.J., and Harvey J. Leptin inhibits epileptiform-like activity in rat hippocampal neurones via PI3-kinase-driven activation of BK channels. J. Physiol. 545 3 (2002) 933-944
96. Sheth R. Adolescent issues in epilepsy. J. Child Neurol. 17 Sl2 (2002) S23-S27
97. Shi Y., Kanaani J., Menard-Rose V., Ma Y.H., Chang P.Y., Hanahan D., Tobin A., Grodsky G., and Baekkeskov S. Increased expression of GAD65 and GABA in pancreatic beta-cells impairs first-phase insulin secretion. Am. J. Physiol. 279 (2000) E684-E694
98. Sivitz W.I., Walsh S.A., Morgan D.A., Thomas M.J., and Haynes W.G. Effects of leptin on insulin sensitivity in normal rats. Endocrinology 138 (1997) 3395-3401
99. + channels in hypothalamic neurons of lean, but not obese rats. Nat. Neurosci. 3 (2000) 757-758
100. Stefan N., Bunt J.C., Salbe A.D., Funahashi T., Matsuzawa Y., and Tataranni P.A. Plasma adiponectin concentrations in children: relationship with obesity and insulinemia. J. Clin. Endocrinol. Metab. 87 (2002) 4652-4656
101. Thearle M., and Aronne L.J. Obesity and pharmacologic therapy. Endocrinol. Metab. Clin. North Am. 32 (2003) 1005-1024
102. Unger R.H. Lipotoxic diseases. Annu. Rev. Med. 53 (2002) 319-336
103. van den Pol A.N. Weighing the role of hypothalamic feeding neurotransmitters. Neuron 40 (2003) 1059-1061
104. Verrotti A., Basciani F., De Simone M., Trotta D., Morgese G., and Chiarelli F. Insulin resistance in epileptic girls who gain weight after therapy with valproic acid. J. Child Neurol. 17 (2002) 265-268
105. Verrotti A., Basciani F., Morresi S., de Martino M., Morgese G., and Chiarelli F. Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid. Neurology 53 1 (1999) 230-232
106. Vollenweider P., Randin D., Tappy L., Jequier E., Nicod P., and Scherrer U. Impaired insulin-induced sympathetic neural activation and vasodilation in skeletal muscle in obese humans. J. Clin. Invest. 93 60 (1994) 2365-2371
107. Vorum H., Gram L., and Honore B. Valproate and palmitate binding to serum albumin in valproate-treated patients: relation to obesity. Epilepsy Res. 16 (1993) 55-64
108. Wabitsch M., Hauner H., Heinze E., Bockamann A., Benz R., Mayer H., and Teller. Body fat distribution and steroid hormone concentrations in obese adolescent girls before and after weight reduction. J. Clin. Endocrinol. Metab. 80 (1995) 3469-3475
109. Wabitsch M., Jensen P.B., Blum W.F., Christoffersen C.T., Englaro P., Heinze E., Rascher W., Teller W., Tornqvist H., and Hauner H. Insulin and cortisol promote leptin production in cultured human fat cells. Diabetes 45 (1996) 1435-1438
110. Wang J., Obici S., Morgan K., Barzilai N., Feng Z., and Rossetti L. Overfeeding rapidly induces leptin and insulin resistance. Diabetes 50 (2001) 2786-2791
111. Wang M.Y., Lee Y., and Unger R.H. Novel form of lipolysis induced by leptin. J. Biol. Chem. 17 (1999) 541-544
112. Wirrell E.C. Valproic acid-associated weight gain in older children and teens with epilepsy. Pediatr. Neurol. 28 (2003) 126-129
113. Wren A.M., Seal L.J., Cohen M.A., Brynes A.E., Frost G.S., Murphy K.G., Dhillo W.S., Ghatei M.A., and Bloom S.R. Gherlin enhances appetite and increases food intake in humans. J. Clin. Endocrinol. Metab. 86 (2001) 5992-5995
114. Yoshikawa H., Tajiri Y., Sako Y., Hashimoto T., Umeda F., and Nawata H. Effects of free fatty acids on beta-cell functions: a possible involvement of peroxisome proliferator-activated receptors alpha or pancreatic/duodenal home box. Metabolism 50 (2001) 613-618
115. Zimmermann U., Kraus T., Himmerich H., Schuld A., and Pollmacher T. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J. Psychiatr. Res. 37 (2003) 193-220